| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SAN FRANCISCO—Burrill & Co. announced recently that Burrill Capital Fund IV L.P., which commencedoperations at the beginning of December, launched with aggregate capital commitments of $313 million
 
"We are pleased to have surpassed our initialgoal of $300 million in capital commitments for the first close," says G.Steven Burrill, CEO of Burrill & Co., a global life sciences financialservices firm. "We look forward to achieving our final goal of $500million in capital commitments by June 2012." 

The fund will invest globally in the lifesciences, including early- to late-stage investments in therapeutics,diagnostics, medical devices, healthcare delivery, wellness, and digitalhealth.
 
 
Founded in 1994, Burrill & Co. is adiversified global financial services firm focused on the life sciencesindustry. With more than $1 billion in assets under management, the firm'sbusinesses include venture capital, private equity, merchant banking, andmedia. Headquartered in SanFrancisco, the company oversees a global network of offices throughout theUnited States, Latin America, Europe, and Asia. For more information visit: .
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue